Market Tracker

12/08 11:05am ET

Progenics Pharmaceuticals Inc (NASDAQ:PGNX)

8.82
BATS BZX Real-Time Price
As of 11:05am ET
 +0.26 / +3.04%
Today’s Change
3.61
Today|||52-Week Range
9.23
+43.88%
Year-to-Date
Why Progenics Pharmaceuticals, Inc. Stock Climbed 76.5% in November
Dec 06 / MotleyFool.com - Paid Partner Content
Valeant (VRX) Ups Sales Force to Support Xifaxan/Relistor
Nov 30 / Zacks.com - Paid Partner Content
'Yuge' Sector Rotation Will Continue
Dec 01 / TheStreet.com - Paid Partner Content
 

Today’s Trading

Previous close8.56
Today’s open8.54
Day’s range8.45 - 8.85
Volume31,810
Average volume (3 months)1,327,668
Market cap$631.9M
Dividend yield--
Data as of 11:05am ET, 12/08/2016

Growth & Valuation

Earnings growth (last year)-1,033.33%
Earnings growth (this year)+112.50%
Earnings growth (next 5 years)+7.00%
Revenue growth (last year)-80.45%
P/E ratio54.9
Price/Sales49.26
Price/Book6.97

Competitors

 Today’s
change
Today’s
% change
ENTAEnanta Pharmaceutica...+0.09+0.28%
KERXKeryx Biopharmaceuti...-0.05-0.83%
GBTGlobal Blood Therape...+0.40+2.51%
CLLSCellectis SA-0.19-1.09%
Data as of 11:05am ET, 12/08/2016

Financials

Next reporting dateMarch 16, 2017
EPS forecast (this quarter)-$0.19
Annual revenue (last year)$8.7M
Annual profit (last year)-$39.1M
Net profit margin-450.81%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Mark Robert Baker
Vice President-
Operations
Meryl J. Longval
Corporate headquarters
Tarrytown, New York

Forecasts